Methods of treating mutant lymphomas

1. A method of treating a MYD88-mutant B-cell lymphoma in a patient in need thereof, comprising administering a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof to the patient;

wherein Compound A is N-(2-((1r,4r)-4-((6-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) amino)ethyl)-2-azaspiro[3.3]heptan-2-yl)methyl)cyclohexyl)-5-(2-hydroxypropan-2-yl)benzo[d]thiazol-6-yl)-6-(trifluoromethyl)picolinamide. wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a dose of up to 1600 mg to the patient.

2. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a dose of up to 900 mg to the patient.

3. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a dose of up to 400 mg to the patient.

4. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a dose of up to 300 mg to the patient.

5. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a dose of from about 300 mg to about 900 mg.

6. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a dose of from about 100 mg to about 300 mg.

7. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a dose of from about 30 mg/m 2 to about 90 mg/m 2 .

8. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a dose of from about 10 mg/m 2 to about 40 mg/m 2 .

9. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered orally to the patient.

10. The method of claim 9 , wherein the oral administration of Compound A to the patient comprises solutions, suspensions, emulsions, tablets, pills, capsules, powders, or sustained-release formulations.

11. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered intravenously to the patient.

12. The method of claim 11 , wherein the intravenous administration of Compound A to the patient comprises sterile injectable solutions.

13. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered to the patient once weekly.

14. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered to the patient twice weekly.

15. The method of claim 14 , wherein the administration of Compound A or a pharmaceutically acceptable salt thereof is on day 1 and day 2 of the week.

16. The method of claim 14 , wherein the administration of Compound A or a pharmaceutically acceptable salt thereof is on day 1 and day 4 of the week.

17. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered to the patient once weekly in week 1 and week 2 in a 3 week administration cycle.

18. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered to the patient twice weekly in week 1 and week 2 in a 3 week administration cycle.

19. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered to the patient once weekly in week 1 and week 2 in a 4 week administration cycle.

20. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered to the patient twice weekly in week 1 and week 2 in a 4 week administration cycle.

21. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered to the patient once weekly in week 1 and week 3 in a 4 week administration cycle.

22. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered to the patient twice weekly in week 1 and week 3 in a 4 week administration cycle.

23. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered to the patient once weekly in weeks 1-3 in a 4 week administration cycle.

24. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered to the patient twice weekly in weeks 1-3 in a 4 week administration cycle.

25. The method of claim 1 , wherein Compound A or a pharmaceutically acceptable salt thereof is administered as a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient or carrier.

26. The method of claim 25 , wherein the one or more pharmaceutically acceptable excipient or carrier comprises one or more diluents, preservatives, binders, lubricants, disintegrators, swelling agents, fillers, or stabilizers.

27. The method of claim 25 , wherein the one or more pharmaceutically acceptable excipient or carrier comprises one or more buffers, surfactants, dispersants, emulsifiers, or viscosity modifying agents.

28. The method of claim 1 , wherein the MYD88-mutant B-cell lymphoma is selected from ABC DLBCL, primary CNS lymphomas, primary extranodal lymphomas, Waldenstrom macroglobulinemia, Hodgkin's lymphoma, primary cutaneous T-cell lymphoma and chronic lymphocytic leukemia.

29. The method of claim 1 , wherein the patient has received at least one prior therapy.

30. The method of claim 1 , wherein the patient is a human.